It helps neutralize free radicals, detoxify the liver, and support immune responses
Although numerous experimental studies, primarily in animal models, have demonstrated the beneficial effects of GLP-1 agonists (e.g., liraglutide and exenatide) in sepsis, including reduced inflammation, improved organ function, and prolonged survival, their clinical use in humans is not yet routine and remains under investigation
Because of this multi-receptor approach, early data on Retatrutide has shown higher average body weight reduction compared to single-agonist treatments like Ozempic
However, significant risks and considerations must be weighed carefully: Gastrointestinal adverse effects : Both gastric sleeve and semaglutide delay gastric emptying and can cause nausea, vomiting, abdominal discomfort, and constipation
Injectable semaglutide should be clear, colorless, and free of particles